Tyro Capital Management LLC Makes New $4.69 Million Investment in LENZ Therapeutics, Inc. $LENZ

Tyro Capital Management LLC bought a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 100,672 shares of the company’s stock, valued at approximately $4,689,000. LENZ Therapeutics accounts for 1.7% of Tyro Capital Management LLC’s holdings, making the stock its 10th largest holding. Tyro Capital Management LLC owned about 0.32% of LENZ Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Skandinaviska Enskilda Banken AB publ increased its stake in LENZ Therapeutics by 99.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 185,642 shares of the company’s stock worth $8,647,000 after purchasing an additional 92,362 shares during the period. Sovran Advisors LLC lifted its position in shares of LENZ Therapeutics by 164.5% during the third quarter. Sovran Advisors LLC now owns 106,920 shares of the company’s stock worth $4,980,000 after purchasing an additional 66,497 shares during the last quarter. Versant Venture Management LLC purchased a new stake in shares of LENZ Therapeutics during the third quarter valued at $123,758,000. Saturn V Capital Management LP purchased a new stake in shares of LENZ Therapeutics during the second quarter valued at $10,033,000. Finally, Stempoint Capital LP bought a new position in shares of LENZ Therapeutics in the second quarter worth about $5,390,000. Institutional investors own 54.32% of the company’s stock.

Wall Street Analyst Weigh In

LENZ has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Thursday, January 22nd. Zacks Research lowered shares of LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Finally, Wall Street Zen raised shares of LENZ Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 1st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, LENZ Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $56.40.

LENZ Therapeutics Price Performance

NASDAQ:LENZ opened at $12.30 on Tuesday. LENZ Therapeutics, Inc. has a 1-year low of $11.21 and a 1-year high of $50.40. The company has a 50-day moving average of $15.33 and a 200 day moving average of $26.67. The firm has a market cap of $384.87 million, a PE ratio of -5.83 and a beta of 0.52.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.